Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors

Reports of Practical Oncology and Radiotherapy

Volumn 18, Issue 2, 2013, Pages 67-75

  Conde, Sofia ^a   Borrego, Margarida ^a   Teixeira, Tânia ^a   Teixeira, Rubina ^a   Sá, Anabela ^a   Soares, Paula ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Adjuvant chemotherapy; Neoadjuvant infusional chemoradiotherapy; Neoadjuvant oral chemoradiotherapy; Prognostic factors; Rectal cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; TEGAFUR; URACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECTUM CANCER; TREATMENT RESPONSE;

EID: 84875632830     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2012.07.010     Document Type: Article

References (41)

1. National Institutes of Health Consensus Conference Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
2. Feliu J., Calvillo J., Escribano A., et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol 2002, 13:730-736.
3. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
4. Bosset J.F., Calais G., Mineur L., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results of EORTC 22921. J Clin Oncol 2005, 23:5620-5627.
5. De Paoli A., Chiara S., Luppi G., et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006, 17:246-251.
6. ®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Phys 2006, 66:762-771.
7. Kim J.C., Kim T.W., Kim J.H., et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005, 63:346-353.
8. De la Torre A., Garcia-Berrocal M.I., Arias F., et al. Preoperative chemoradiatiotherapy fr rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Phys 2008, 70:102-110.
9. Janjan N.A., Crane C., Feig B.W., et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001, 24:107-112.
10. Roh M.S., Petrelli N., Wieand L., et al. Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 2001, 20:123. [Abstract 490].
11. Kim D.Y., Jung K.H., Kim T.H., et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007, 67:378-384.
12. Crane C.H., Skibber J.M., Birnbaum E.H., et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Phys 2003, 57:84-89.
13. Gerard J.P., Conroy T., Bonnetain F., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
14. Fernandez-Martos C., Aparicio J., Bosch C., et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-up. J Clin Oncol 2004, 22:3016-3022.
15. Compton C.C., Fielding L.P., Bugart L.J., et al. Prognostic factors in colorectal cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 2000, 124:979-994.
16. Carriquiry L.A., Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer?. Dis Colon Rectum 1999, 42:921-929.
17. Park Y., Sohn S., Seong J., et al. Serrum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006, 93:145-150.
18. Rodel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
19. García-Aguilar J., de Anda E.H., Sirivongs P., et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003, 298-304.
20. Capirci C., Valentini V., Cionini L., et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72(1):99-107.
21. Collette L., Bosset J.F., Den Dulk M., et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organization for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386.
22. Myerson R.J., Garofalo M.C., Naqa I.E., et al. Elective Clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009, 74:824-830.
23. Roels S., Duthoy W., Haustermans K., et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006, 65:1129-1142.
24. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS; 2006.
25. AJCC Cancer staging handbook 2001, Springer. 6th ed.
26. Bosset J.F., Calais G., Daban A., et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance: Report of the 22921 radomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer 2004, 40:219-224.
27. Janjan N.A., Khoo V.S., Abbruzzese J., et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999, 44:1027-1038.
28. Minsky B.D., Cohen A.M., Enker W.E., et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997, 37:289-295.
29. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502-507.
30. Meta-analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308.
31. Grem J.L. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 1997, 24(Suppl. 18):8-18.
32. Valentini V., Coco C., Picciocchi A., et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002, 53:664-674.
33. Francois Y., Nemoz C., Baulieux J., et al. Influence of the interval between radiation therapy and surgery on downstaging and rate of sphincter sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396-2402.
34. Das P., Skibber J.M., Rodriguez-Bigas M.A., et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007, 109:1750-1755.
35. Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11(September (9)):835-844.
36. Conde S., Borrego M., Teixeira T., et al. Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer. Rep Pract Oncol Radiother 2010, 15:51-59.
37. Kim N.K., Baik S.H., Seong J.S., et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg 2006, 244(December (6)):1024-1030.
38. Pucciarelli S., Toppan P., Friso M.L., et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004, 47:1798-1807.
39. Valentini V., Beets-Tan R., Borras J.M., et al. Evidence and research in rectal câncer. Radiother Oncol 2008, 87:449-474.
40. Valentini V., Aristei C., Glimelius B., et al. Multidisciplinary rectal cancer management: 2nd Europena Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009, 92:148-163.
41. QUASAR Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007, 370:2020-2029.